You are viewing: US Theranostics Market analysis
Part of: Theranostics Market (Global)

The US Theranostics Market was valued at $1117.5 Million in 2023 and projected to reach to $2319.1 Million by 2028, representing a compound annual growth rate of CAGR 15.7%. The US theranostics market is poised for robust expansion through 2028, with a 15.7% CAGR reflecting strong demand for integrated diagnostic-therapeutic platforms.

US Theranostics Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Theranostics Market Trends and Insights

  • The US market is driven by advanced diagnostic and therapeutic integration capabilities, robust healthcare infrastructure, and significant investment in precision medicine initiatives.
  • The US theranostics sector benefits from strong regulatory frameworks, high adoption rates of innovative medical technologies, and a well-established reimbursement landscape that supports market expansion. Growth in the US theranostics market is fueled by increasing prevalence of chronic diseases, rising demand for personalized treatment approaches, and accelerating development of companion diagnostics.
  • The US maintains a leadership position in theranostics innovation, with major pharmaceutical and diagnostic companies investing heavily in research and development.
  • By 2028, the US market is expected to capture significant value as healthcare providers increasingly adopt theranostic solutions for improved patient outcomes and cost-effective treatment strategies..

Key Market Statistics

  • CAGR (2023-2028) CAGR 15.7%
  • Market Size, 2023 ~USD 1117.5 Million
  • Forecast, 2028 ~USD 2319.1 Million
  • Country US

US Theranostics Market Overview

Market Valuation Growth :

The US theranostics market reached $1,117.5 million in 2023 and is projected to grow to $2,319.1 million by 2028, driven by increasing adoption of precision medicine and integrated diagnostic-therapeutic solutions across major healthcare systems.

Advanced Healthcare Infrastructure :

The US benefits from world-class medical facilities, extensive R&D capabilities, and strong regulatory frameworks that accelerate theranostics innovation and commercialization, positioning it as a global leader in precision healthcare technologies.

Precision Medicine Investment :

Significant federal and private sector investments in precision medicine initiatives, including the All of Us Research Program, are fueling demand for theranostic solutions that enable personalized treatment approaches across oncology, cardiology, and neurology.

Reimbursement Landscape :

Expanding Medicare and private insurance coverage for theranostic procedures, combined with favorable health economic outcomes, is driving adoption among US hospitals, diagnostic centers, and specialty clinics.

US Theranostics Market Dynamics

  • Key drivers include increasing cancer prevalence, growing adoption of companion diagnostics, and healthcare providers' shift toward value-based care models that reward precision treatment outcomes.
  • Technological advancements in molecular imaging, biomarker identification, and targeted drug delivery are enabling more effective theranostic applications. Regulatory support from the FDA, coupled with rising healthcare expenditure and patient awareness of personalized medicine benefits, will continue to accelerate market penetration.
  • The US market will likely see consolidation among diagnostic and pharmaceutical companies, increased venture capital investment in theranostics startups, and expanded clinical applications beyond oncology into cardiovascular and neurological disorders..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • The US theranostics market is valued at $1,117.5 million in 2023 and will nearly double to $2,319.1 million by 2028.
    • The US market demonstrates a robust 15.7% CAGR, outpacing global growth and reflecting strong adoption of precision medicine.
    • The US theranostics sector is supported by advanced healthcare infrastructure, favorable reimbursement policies, and significant R&D investment.
    • The US market leadership is driven by increasing demand for personalized diagnostics and therapeutics in oncology and other chronic disease management.

    Theranostics Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment THERANOSTICS CENTERS (End User)
    Forecast Period 2023-2028
    Growth Rate CAGR of 15.5% from 2023 to 2028
    Largest Segment RADIOPHARMACEUTICALS (Product)
    Market Size Base Year (Billions) ~USD 2.09 (2023)
    Revenue Forecast (Billions) ~USD 4.3 (2028)
    Segments Covered Product, Type, Application, End User

    US Theranostics Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Diagnostic Imaging
    • Ivd/Biomarker Screening
    • Radiopharmaceuticals
    • Software & Services

    By Type

    • Iodine-131
    • Lutetium-177
    • Other Radiopharmaceuticals
    • Radium-223
    • Samarium-153
    • Yttrium-90

    By Application

    • Bone Metastasis
    • Other Applications
    • Other Cancer
    • Other Cancers
    • Prostate Cancer

    By End User

    • Hospitals And Cancer Care Centers
    • Research And Academic Centers
    • Theranostics Centers

    Target Audience

    • Pharmaceutical & Biotech Companies : Need US market intelligence to develop theranostic drug-diagnostic companion products, understand reimbursement landscapes, and identify partnership opportunities with diagnostic firms to capture the growing precision medicine market.
    • Diagnostic & Medical Device Manufacturers : Require detailed US market data to guide R&D investments in theranostic platforms, assess competitive threats, and develop integrated solutions that align with hospital procurement and precision medicine adoption trends.
    • Healthcare Providers & Hospital Systems : Need market insights to evaluate theranostic technology investments, understand clinical and economic outcomes, and make informed decisions about implementing precision medicine programs across their networks.
    • Investment & Private Equity Firms : Seek comprehensive US market analysis to identify high-growth theranostics companies for investment, evaluate acquisition targets, and assess portfolio company growth potential in the precision medicine sector.
    • Healthcare Consultants & Analysts : Require validated US market data, growth forecasts, and trend analysis to support client advisory work, competitive benchmarking, and strategic planning in the rapidly evolving theranostics and precision medicine landscape.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise US market valuation ($1,117.5M in 2023) and verified forecast data ($2,319.1M by 2028) to support investment decisions, business planning, and competitive positioning in the high-growth theranostics sector.
    • US-Specific Growth Drivers : Understand unique US market dynamics including precision medicine initiatives, reimbursement trends, regulatory pathways, and healthcare infrastructure advantages that differentiate the US market from global competitors.
    • Strategic Market Segmentation : Access detailed insights into US theranostics applications by disease type, technology platform, and end-user segments to identify high-opportunity niches and optimize product development and go-to-market strategies.
    • Competitive Intelligence : Benchmark your organization against US market leaders, identify emerging players, and analyze competitive positioning to inform M&A strategies, partnership opportunities, and market entry decisions.
    • Regulatory & Reimbursement Roadmap : Navigate FDA approval pathways, Medicare/insurance coverage policies, and health economic requirements specific to the US market to accelerate commercialization and maximize market adoption potential.

    Frequently asked questions

    What is the current size of the US theranostics market?

    The US theranostics market was valued at $1,117.5 million in 2023 and is expected to grow significantly through 2028.

    What is the projected growth rate for the US theranostics market?

    The US theranostics market is projected to grow at a compound annual growth rate of 15.7% from 2023 to 2028.

    What will the US theranostics market size be in 2028?

    The US theranostics market is forecasted to reach $2,319.1 million by 2028, more than doubling from 2023 levels.

    What factors are driving growth in the US theranostics market?

    Key drivers include increasing prevalence of chronic diseases, rising adoption of precision medicine, development of companion diagnostics, and strong healthcare infrastructure with favorable reimbursement policies.

    Why is the US theranostics market growing faster than the global average?

    The US market benefits from advanced healthcare systems, robust regulatory frameworks, significant pharmaceutical R&D investment, and high adoption rates of innovative medical technologies compared to other regions.

    RESEARCH METHODOLOGY

    The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Theranostics Market Size, and Share

    *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Estimation Methodology

    In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

    • Generating a list of major global players operating in the theranostics market.
    • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
    • Revenue mapping of major players to cover a major share of the global market share, as of 2022
    • Extrapolating the global value of the theranostics market industry

    Theranostics Market Size, and Share

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

    Market Definition

    Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

    Key Stakeholders

    • Senior Management
    • End Users
    • R&D Department
    • Finance/Procurement Department

    Objectives of the Study

    • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
    • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
    • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
    • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographic Analysis

    • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
    • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

    Get the Full Theranostics Market Report

    Full forecast, segment splits, and company analysis for all Theranostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status